Vlad Coric Purchases 121,951 Shares of Biohaven Ltd. (NYSE:BHVN) Stock

Biohaven Ltd. (NYSE:BHVN) CEO Vlad Coric bought 121,951 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was purchased at an average cost of $41.00 per share, for a total transaction of $4,999,991.00. Following the completion of the transaction, the chief executive officer now owns 1,788,417 shares of the company’s stock, valued at $73,325,097. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Biohaven Stock Down 1.7 %

Biohaven stock opened at $38.32 on Tuesday. Biohaven Ltd. has a 12-month low of $12.35 and a 12-month high of $62.21. The stock has a 50-day simple moving average of $51.63 and a 200 day simple moving average of $41.70.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.40). Sell-side analysts anticipate that Biohaven Ltd. will post -5.85 EPS for the current year.

Institutional Trading of Biohaven

A number of institutional investors have recently bought and sold shares of the business. Thompson Davis & CO. Inc. acquired a new position in Biohaven during the fourth quarter valued at approximately $214,000. Prevail Innovative Wealth Advisors LLC bought a new stake in shares of Biohaven in the fourth quarter worth $230,000. Private Advisor Group LLC acquired a new position in shares of Biohaven during the 4th quarter worth about $231,000. Capstone Investment Advisors LLC bought a new position in Biohaven in the fourth quarter valued at approximately $235,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Biohaven in the third quarter valued at $236,000. Institutional investors and hedge funds own 88.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BHVN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 target price on shares of Biohaven in a research report on Tuesday, April 9th. HC Wainwright increased their price target on shares of Biohaven from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. JPMorgan Chase & Co. lifted their price target on shares of Biohaven from $32.00 to $56.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. TD Cowen upped their target price on shares of Biohaven from $35.00 to $55.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a report on Thursday, April 18th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $52.00.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.